Dr Saad Usmani speaks at the 2019 ASH meeting about the results from the CANDOR study which examined the combination of daratumumab, carfilzomib and dexamethasone for the treatment of patients with relapse/refractory multiple myeloma (MM).

He explains that this drug combination significantly increased survival for this patient population.

Watch our interview with Dr Usmani here. 

Read more about the study here.